Latest filings (excl ownership)
8-K
Other Events
22 Apr 24
424B5
Prospectus supplement for primary offering
19 Apr 24
424B5
Prospectus supplement for primary offering
17 Apr 24
8-K
Regulation FD Disclosure
15 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
8-K
Other Events
12 Mar 24
424B7
Prospectus with selling stockholder info
12 Mar 24
8-K
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Other Events
5 Oct 23
424B5
Prospectus supplement for primary offering
4 Oct 23
8-K
Other Events
2 Oct 23
424B5
Prospectus supplement for primary offering
2 Oct 23
424B5
Prospectus supplement for primary offering
2 Oct 23
S-3ASR
Automatic shelf registration
2 Oct 23
8-K
Regulation FD Disclosure
27 Sep 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
8-K
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
31 Jul 23
8-K
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
28 Jul 23
8-K
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
31 May 23
8-K
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
12 May 23
S-8
Registration of securities for employees
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Departure of Directors or Certain Officers
4 May 23
8-K
Investor Presentation March 2023
23 Mar 23
8-K
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
23 Mar 23
DEFA14A
Additional proxy soliciting materials
23 Mar 23
DEF 14A
Definitive proxy
23 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Regulation FD Disclosure
10 Jan 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Biohaven LTD. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
9 Nov 22
424B4
Prospectus supplement with pricing info
24 Oct 22
EFFECT
Notice of effectiveness
21 Oct 22
S-1MEF
Registration of additional securities for an S-1
20 Oct 22
S-1/A
IPO registration (amended)
20 Oct 22
Latest ownership filings
4
Gregory Bailey
25 Apr 24
4
Gregory Bailey
23 Apr 24
4
JOHN W CHILDS
23 Apr 24
4
Vlad Coric
23 Apr 24
4
JOHN W CHILDS
5 Apr 24
4
Vlad Coric
5 Apr 24
4
JOHN W CHILDS
8 Mar 24
4
Vlad Coric
8 Mar 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G
BlackRock Inc.
6 Feb 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
JOHN W CHILDS
10 Jan 24
4
Vlad Coric
10 Jan 24
4
George C. Clark
4 Jan 24
4
Bruce Car
4 Jan 24
4
Kimberly Gentile
4 Jan 24
4
Matthew Buten
4 Jan 24
4
Vlad Coric
4 Jan 24
4
Irina Antonijevic
29 Dec 23
144
Notice of proposed sale of securities
29 Dec 23
4
Matthew Buten
6 Nov 23
4
Vlad Coric
6 Nov 23
4
George C. Clark
6 Nov 23
4
Kimberly Gentile
6 Nov 23
4
Bruce Car
6 Nov 23
SC 13G
Point72 Asset Management, L.P.
18 Oct 23
4
JOHN W CHILDS
10 Oct 23
4
Vlad Coric
10 Oct 23
4
Matthew Buten
6 Oct 23
4
Gregory Bailey
6 Oct 23
4
JOHN W CHILDS
31 Aug 23
4
JOHN W CHILDS
7 Aug 23
4
Gregory Bailey
4 May 23
4
Kishan Mehta
4 May 23
4
JULIA P GREGORY
4 May 23
4
Irina Antonijevic
4 May 23
4
JOHN W CHILDS
4 May 23
4
Michael Thomas Heffernan
4 May 23